Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 305

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 305
---
, 2022, 2023 and 2024                                                
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Report s of Independent Registered Public Accounting Firm s (Deloitte & Associés PCAOB ID 1756 - PricewaterhouseCoopers Audit - PCAOB ID 1347)  
  Consolidated Statements of Financial Position as of December 31, 2022, 2023 and 2024                                                            
  Consolidated Statements of Income (Loss) for the Years Ended December 31, 2022, 2023 and 2024                                                   
  Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December 31, 2022, 2023 and 2024                                     
  Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2023 and 2024                                                      
  Consolidated Statements of Changes in Shareholders’ Equity for the Years Ended December 31, 2022, 2023 and 2024                                 
  Notes to the Consolidated Financial Statements                                                                                                  

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS

To the shareholders and the Board of Directors of Innate Pharma S. A.

Opinion on the Financial Statements

We have audited the accompanying consolidated statements of financial position of Innate Pharma S. A. and its subsidiary (the “ Company”) as of December 31, 2024, the related consolidated statements of income (loss), comprehensive income (loss), change in shareholders’ equity, and cash flows, for the year ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year then ended, in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB).

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established inInternal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated April 30,